Avoidance diets--how selective should we be?

S L Taylor; R K Bush; W W Busse

PubMed · 3475554

Avoidance diets--how selective should we be?

Abstract

Selective avoidance diets are the most common means of treatment for food allergies and other types of food sensitivities. With IgE-mediated food allergies, adverse reactions can occur in some patients to very small amounts of the offending food; therefore, strict avoidance of the offending food must be accomplished. With other, non-immunological types of food sensitivities, such as lactose intolerance and sulfite sensitivity, the patients are able to tolerate some, although variable, amounts of the offending substance. Thus, the degree of tolerance is an important concern in the construction of safe and effective avoidance diets. Another issue in the development of selective avoidance diets is the presence of the allergen in specific foods. For example, the peanut allergen is a protein which is not present in peanut oil. Consequently, peanut oil is safe to consume for peanut-allergic patients. Cross-reactivity is yet another concern in the development of selective avoidance diets. Cross reactions can occur between related species of legumes, crustacea, eggs, and milk for example. The construction of a safe and effective avoidance diet for food allergies and sensitivities requires consideration of several important issues and is a responsibility that should not be taken lightly.

Explore related subjects

Cross Reactions Food Food Hypersensitivity Food Preferences Humans Immune Tolerance Immunoglobulin E Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

S L Taylor, R K Bush, W W Busse. Avoidance diets--how selective should we be?. https://pubmed.ncbi.nlm.nih.gov/3475554/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

SuperHapten: a comprehensive database for small immunogenic compounds.

The immune system protects organisms from foreign proteins, peptide epitopes and a multitude of chemical compounds. Among these, haptens are small molecules, eliciting an immune response when conjugated with carrier molecules. Known haptens are xenobiotics or natural compounds, which can induce a number of autoimmune diseases like contact dermatitis or asthma. Furthermore, haptens are utilized in the development of biosensors, immunomodulators and new vaccines. Although hapten-induced allergies account for 6-10% of all adverse drug effects, the understanding of the correlation between structural and haptenic properties is rather fragmentary. We have developed a manually curated hapten database, SuperHapten, integrating information from literature and web resources. The current version of the database compiles 2D/3D structures, physicochemical properties and references for about 7500 haptens and 25,000 synonyms. The commercial availability is documented for about 6300 haptens and 450 related antibodies, enabling experimental approaches on cross-reactivity. The haptens are classified regarding their origin: pesticides, herbicides, insecticides, drugs, natural compounds, etc. Queries allow identification of haptens and associated antibodies according to functional class, carrier protein, chemical scaffold, composition or structural similarity. SuperHapten is available online at http://bioinformatics.charite.de/superhapten.

Cross Reactions↗

PubMed2006

Multiplex real-time reverse transcription-PCR assay for determination of hepatitis C virus genotypes.

A variety of methods have been used to determine hepatitis C virus (HCV) genotypes. Because therapeutic decisions for chronic HCV-related hepatitis are made on the basis of genotype, it is important that genotype be accurately determined by clinical laboratories. Existing methods are often subjective, inaccurate, manual, time-consuming, and contamination prone. We therefore evaluated real-time reverse transcription-PCR (RT-PCR) reagents that have recently become commercially available (Abbott HCV Genotype ASR). The assay developed by our laboratory starts with purified RNA and can be performed in 4 to 5 h. An initial evaluation of 479 samples was done with a restriction fragment length polymorphism (RFLP) method and the RT-PCR assay, and discrepant samples were sequenced. An additional 1,200 samples were then tested, and data from all assays were used to evaluate the efficiency and specificity of each genotype-specific reaction. Good correlation between results by the two methods was seen. Discrepant samples included those indeterminate by the RT-PCR assay (n = 110) and a subset that were incorrectly called 2a by the RFLP method (n = 75). The real-time RT-PCR assay performed well with genotype 1, 2, and 3 samples. Inadequate numbers of samples were available to evaluate fully genotypes 4, 5, and 6. Analysis of each primer-probe set demonstrated that weak cross-reactive amplifications were common but usually did not interfere with the genotype determination. However, in about 1% of samples, two or more genotypes amplified at roughly equivalent amounts. Further studies are necessary to determine whether these mixed-genotype samples are true mixtures or a reflection of occasional cross-reactive amplifications.

Cross Reactions↗

PubMed2006

Determination of everolimus in whole blood using the Abbott IMx sirolimus microparticle enzyme immunoassay.

OBJECTIVES: Everolimus (Certican) is a new immunosuppressant derived from sirolimus (Rapamune) with a 2-hydroxyethyl chain at position 40 of the macrolide ring. The aim of our study was to evaluate the possible determination of everolimus in whole blood using a commercialized microparticle enzyme immunoassay for sirolimus determination. DESIGN AND METHODS: Everolimus concentrations were determined in blood samples from 11 kidney transplant patients (n=51) and different control materials (n=35) using the Seradyn Innofluor Certican fluorescence polarization immunoassay (FPIA) and the Abbott IMx sirolimus microparticle enzyme immunoassay (MEIA). RESULTS: The MEIA gave a concentration-dependent cross-reactivity with the everolimus, with a linear regression between the assigned values (y) for the Innofluor Certican calibrators and those obtained (x) using this immunoassay: y=0.96x+0.67 (ma68=0.21 microg/L, r=0.974, p<0.001). The within- and between-run coefficients of variation using the MEIA were <or=7.3%. In analyzing the different blood samples from patients and control materials using the MEIA and FPIA, a linear regression was found: MEIA=0.99FPIA-0.46 (ma68=0.32 microg/L, r=0.967, p<0.001). Correcting the MEIA results by means of the linear regression equation found between the assigned values for the Innofluor Certican calibrators and those obtained using this immunoassay led to a reduction in the deviation with respect to the FPIA values. The possible effect of the hematocrit on the results is analogous for both immunoassays. CONCLUSIONS: The Abbott IMx sirolimus MEIA permits the simple and precise determination of everolimus in whole blood, making it a valid alternative for the therapeutic monitoring of this immunosuppressant agent.

Cross Reactions↗